1 Patients experienced a mean of 8.2 AEs; the most frequen
2 Patients experienced attacks often requiring treatment i
3 Patients experienced excess volume reductions of 111% an
4 Patients experienced fever, skin rash, arthralgia and co
5 Patients experienced more days alive and free of deliriu
6 Patients experienced more flares per person-years after
7 uring a median follow-up of 4.3 years, 1,
054 patients experienced a first major CVD event.
8 om January 1, 2019, to March 31, 2020, 6,
083 patients experienced 7,187 hospitalizations for primary
9 months after dislocation of the PCIOL, and
1 patient experienced iris capture of the PCIOL after surg
10 Within 48 hours of transfusion, all but
1 patient experienced an improvement of clinical symptoms.
11 R 12 weeks after end of treatment, whereas
1 patient experienced relapse at week 4 following treatmen
12 In total,
104 patients experienced MACE (median time to event, 36 week
13 a median follow-up of 49.5 months, 5 of
107 patients experienced a local relapse within a median of
14 Twenty-seven required enteric conversion;
11 patients experienced renal allograft failure (10 underwe
15 Among them, 114 (
11%)
patients experienced at least one GI complication and di
16 All
12 patients experienced at least one adverse event during t
17 ntinued due to adverse events and four (
12%)
patients experienced a total of six serious adverse even
18 ysis (mean follow-up of 52+/-22 months),
125 patients experienced 136 hard events (18 cardiac deaths
19 d 15,753 comprised the reference group;
1350 patients experienced community-onset AKI and 464 develop
20 Overall,
136 patients experienced treatment-emergent adverse events,
21 After stopping therapy, 13 of
15 patients experienced a virological relapse.
22 While 3 of
15 patients experienced only transient benefit after 4 week
23 In total, 47 of
152 patients experienced HFS (30.9%), 39.5% with the new oin
24 interquartile range, 1.0-4.3) follow-up,
160 patients experienced the primary end point, and 88 exper
25 (interquartile range: 2.7 to 16.5 years),
17 patients experienced a first LAE, with a cumulative prob
26 Twenty-six (
17%)
patients experienced 5-day failure; SOFA, source of UGIB
27 ne adverse event during treatment: two (
17%)
patients experienced anaemia, eight (67%) neutropenia, a
28 -up of 67.0 and 60.0 days, respectively,
172 patients experienced a vision-threatening complication (
29 -up of 67.0 and 60.0 days, respectively,
172 patients experienced a vision-threatening complication (
30 subclinical THV thrombosis, whereas 5 (
18%)
patients experienced clinically overt obstructive THV th
31 A total of 11
196 patients experienced HO-GNR bacteremia during the study
32 complication, whereas 240 (2%) and 163 (
2%)
patients experienced Grade 1 and Grade 2-3 complications
33 Three hundred eighty (32.
2%)
patients experienced intrahospital cardiovascular events
34 Two (
2%)
patients experienced life-threatening AEs (one had pneum
35 Eleven (52%) of
21 patients experienced stable disease.
36 During follow-up,
23 patients experienced disease progression, whereas 13 pat
37 Seventy-nine (
23%)
patients experienced 1 or more on-treatment serious AEs;
38 238 patients experienced grade 3 or 4 toxicities: 12 (13%) h
39 28 patients experienced 40 serious adverse events; eight of
40 Only
28 patients experienced a second relapse.
41 29 patients experienced 36 clinically significant deteriora
42 Eighty-five (13.
3%)
patients experienced BPAR.
43 Within 30 days of TAVR, 87 (3.
3%)
patients experienced a stroke (TF 58 [3.8%]; TA 29 [2.7%
44 Thirty-seven of the 445 (8.
3%)
patients experienced a cerebral abscess at a median age
45 I], 26 [range, 23-31]) were included, and
30 patients experienced a cardiovascular event during a med
46 (range, 0.1 to 10.1 years), during which
30 patients experienced an ACE.
47 Overall, 18 of
31 patients experienced malignant transformation; of these,
48 Twenty-three of
31 patients experienced tumor progression (median progressi
49 11 (
32%)
patients experienced grade 3 or worse adverse events, of
50 ents underwent liver transplantation, and
35 patients experienced one or more liver-related events.
51 ears (range, 0 to 23 years), 63 (16%) of
383 patients experienced a leukemic transformation to second
52 In the Sapien 3 group,
4 patients experienced annular rupture whereas this compli
53 atic and, before initiation of mexiletine,
4 patients experienced >=1 breakthrough cardiac event on b
54 During maintenance therapy,
4 patients experienced reactivation in risk organs.
55 Forty-eight (20.
4%)
patients experienced ulcer rebleeding and 46 (19.6%) dev
56 were normotensive at first presentation,
40 patients experienced hypotension during their ED stay.
57 Thirteen of 58 (22.
41%)
patients experienced some kind of complication in the re
58 atal myocardial infarction, and stroke),
410 patients experienced cardiac events, and 561 patients di
59 A total of 11
424 patients experienced RD after cataract surgery, with an
60 Overall, 79 (9.
5%)
patients experienced HAT, E-HAT was diagnosed in 23, and
61 Within 30 days, 13 (0.
50%)
patients experienced a TIA (TF 10 [0.67%]; TA 3 [0.27%];
62 During dose finding, 1/
6 patients experienced a DLT (grade 3 decrease in ejection
63 Six eyes of
6 patients experienced immediate post-laser IOP spike (>5
64 a median 3.8 years of follow-up, 219 (22.
6%)
patients experienced the primary outcome (136 CV events
65 Twenty-three (9.
6%)
patients experienced a CDI-related complication, includi
66 27 (45%) of
60 patients experienced a serious adverse event.
67 Over the total study period, 147 (
67%)
patients experienced at least one treatment-emergent adv
68 ition to standard of care until at least
691 patients experienced an adjudicated event included in th
69 7 patients experienced distressing pain according to Visua
70 In the TEP group, 39 (20.
7%)
patients experienced pain, compared with 62 (33.2%) pati
71 ed wound healing, were seen in 6 patients;
8 patients experienced severe pain.
72 range, 2.77-10.58) of follow-up, 93 (10.
8%)
patients experienced LTVA including 15 with SCD/aborted
73 Eighty-eight (25.
8%)
patients experienced an asthma exacerbation in the prior
74 In total,
820 patients experienced a primary bleeding outcome and 937
75 At 6 months, three (4%) of
84 patients experienced a major adverse event, which was le
76 Thirty-three (
87%)
patients experienced adverse events.
77 During the study, 98 (
88%)
patients experienced a total of 483 attacks, 77% of whic
78 us reactivations were well controlled, but
9 patients experienced transient BK viremia during the fir
79 ycardia, tachycardia, and asystole); 22 (
9%)
patients experienced 38 nonserious adverse events report
80 llow-up of a mean of 4.1 years, 2183 (23.
9%)
patients experienced a major adverse cardiac event.
81 Three (
9%)
patients experienced five serious treatment-related adve
82 9550 (
96%)
patients experienced no complication, whereas 240 (2%) a
83 rquartile range [IQR]: 2.3 to 7.3 years),
98 patients experienced a MACE.
84 Time with toxicity was the number of days
a patient experienced an AE post-random assignment and bef
85 ents (TEAEs) or the mean duration in which
a patient experienced grade >= 2 TEAEs of nausea, vomiting
86 defining TOX as the mean duration in which
a patient experienced grade >= 3 treatment-emergent advers
87 In total, 19,520 (20.0%)
ACS patients experienced depression within 2 years after the
88 Additionally,
patients experienced the movements of the virtual legs d
89 ALGS patients experienced a trend toward greater freedom from
90 All patients experienced a favorable response, with a mean t
91 All patients experienced AEs (195 in total), with the majori
92 All patients experienced multiple adverse effects, including
93 All patients experienced self-limited symptoms after postexp
94 All patients experienced severe toxicity, with World Health
95 All patients experienced significant decrease in clinical sy
96 All patients experienced some degree of segmental left ventr
97 All patients experienced thrombocytopenia (41 episodes in 27
98 During or after surgery,
all patients experienced episodes of hypotension (systolic b
99 During or after surgery,
all patients experienced episodes of hypotension (systolic b
100 Three patients (8.3% of
all patients) experienced 6 systemic reactions (0.15% of dos
101 Five non-
anticoagulated patients experienced nonfatal thromboembolic events (1.1
102 s in the CGA arm, compared with standard
arm patients, experienced significantly less all grade toxic
103 (1%, 12-week arm) and three (2%, 8-week
arm)
patients experienced a serious adverse event (all unrela
104 The 3
asymptomatic patients experienced a decrease of the viral load (VL) t
105 The three
asymptomatic patients experienced a decrease of the viral load to les
106 Black patients experienced lower odds of VA improvement compar
107 Both patients experienced a prostate-specific antigen decline
108 Both patients experienced deterioration of mental status, res
109 ALGS, FIC1, and
BSEP patients experienced less severely scored pruritus after
110 (53/72) Hybrid Convergent and 55% (23/42)
CA patients experienced >=90% AF burden reduction.
111 acked support, and dual adherence-
challenged patients experienced higher rates of detectable HIV vira
112 During VIT, 11 (34%)
cMCD patients experienced adverse reactions (ARs) (7% in cont
113 During sessions with dialysis
cooling,
patients experienced a 10.6% decrease in perfusion (not
114 Type 2
diabetes patients experienced a higher HR 1.23 (1.21-1.25) of ove
115 Overall
diabetic patients experienced a significantly higher risk of targ
116 Fewer directly
discharged patients experienced a MACE when evaluated with an hsTnT
117 All BPT-
DP+
patients experienced a significant decrease of PC(20) at
118 Long-
DUP patients experienced most of these declines prior to fir
119 es prior to first admission, while short-
DUP patients experienced declines after first admission.
120 Both long- and short-
DUP patients experienced similar declines in psychosocial fu
121 Each patient experienced 1 symptomatic dengue case and 1 DENV
122 Eight patients experienced stable disease > 3 months, includin
123 hs of training with this paradigm, all
eight patients experienced neurological improvements in somati
124 Eleven patients experienced a stroke, 5 of those within 4 weeks
125 Hispanic and Medicare/Medicaid dual-
eligible patients experienced slight decreases in closures.
126 Twelve of 13
evaluable patients experienced hyperamylasemia higher than grade 2
127 RP2D was established at 400 mg (15
evaluable patients experienced two DLTs).
128 tion (OR 1.13 [95% CI 0.86-1.48]), but
fewer patients experienced sedation-related adverse events (OR
129 cohort studied in which one of six or
fewer patients experienced a dose-limiting toxicity.
130 Fifteen patients experienced grade 3 to 4 adverse events; the mo
131 Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had
132 Five patients experienced drug-free remission after rituximab
133 Five patients experienced grade 3 treatment-related AEs.
134 Five patients experienced grade 3-4 toxicities.
135 Five patients experienced other systemic immune-mediated comp
136 Of these,
five patients experienced MRD-negative complete responses, an
137 Four patients experienced colonic perforation, 2 of whom requ
138 Four patients experienced serious AEs; all were considered un
139 One in
four patients experienced treatment delay.
140 isting cardiovascular disease, whereas DC-
GF patients experienced more early rejection, more acute re
141 While DC-
GF patients experienced more early rejection, more acute re
142 , 79.6+/-16.0) mL/min per 1.73 m(2), low-
GFR patients experienced higher risk of death (hazard ratio
143 Although in the iodixanol 270
group patients experienced less heat discomfort (72% vs 86%, r
144 Some
histoplasmosis patients experienced severe disease, apparent diagnostic
145 Intriguingly,
however,
patients experienced significantly fewer (P = 0.016) hal
146 HVHF patients experienced faster correction of metabolic acid
147 its original size (Group 1, n = 99); and
ii)
patients experienced a significant reduction in size (Gr
148 One GT1a-
infected patient experienced late viral relapse after achieving S
149 In addition, HCV-
infected patients experienced a twofold and a nearly 17-fold high
150 Intervention patients experienced less anxiety and depression (median
151 Intervention patients experienced more postextubation stridor (7% vs
152 mitochondrial DNA levels showed that TB-
IRIS patients experienced greater cell death, especially pre-
153 After 10-year
LAR,
patients experienced a significant and clinically releva
154 teristics and postoperative weight loss,
LSG patients experienced significantly higher rates of medic
155 tural and functional brain changes, and
many patients experienced global multisensory hypersensitivit
156 Medicaid patients experienced the most surgical delays.
157 4 mo, but if therapy was repeated every 2
mo patients experienced additive antitumor effects.
158 f treatment with midostaurin (ie, 6
months),
patients experienced significant improvements in total S
159 Overall, 36%
more patients experienced the expanded, in comparison with th
160 However,
more patients experienced sedation-related adverse events (OR
161 Significantly
more patients experienced clinical benefit 1 with mepolizumab
162 Most patients experienced transient fevers and the expected h
163 entral pontine and extrapontine
myelinolysis patients experienced higher intraoperative and periopera
164 Furthermore,
NFLG patients experienced less reverse remodeling but the sam
165 Nine patients experienced a total of 13 unexpected grade 3-5
166 Nine patients experienced hypotension, and 5 had elevated ser
167 Nine patients experienced serious adverse events in the singl
168 Three of
nine patients experienced objective tumor responses (two comp
169 Nineteen patients experienced disease progression while receiving
170 Nineteen patients experienced myelosuppression higher than grade
171 No patient experienced a primary safety end point.
172 No patient experienced any of the predefined MSC-related ha
173 No patient experienced dose-limiting toxicity.
174 No patient experienced greater than grade 1 neurotoxicity,
175 No patient experienced plasma HIV-1 RNA >200 copies/mL duri
176 (80%) of which were from the milk ladder;
no patient experienced anaphylaxis requiring treatment with
177 n six patients and grade 3 nausea in one;
no patient experienced grade 4 diarrhea, and there were no
178 No patients experienced a deterioration in disease activity
179 No patients experienced a serious adverse event.
180 No patients experienced any serious adverse events.
181 No patients experienced hearing decline.
182 No patients experienced organ rejection.
183 on, one patient (5%) experienced DGF, and
no patients experienced NODAT.
184 Five nonobese and two
obese patients experienced potentially toxic piperacillin plas
185 Overall, <1%
of patients experienced an adverse event (AE) that led to G
186 Approximately 12%
of patients experienced cardiotoxicity over a 5-year follow
187 A total of 14%
of patients experienced minor adverse drug reactions (ADRs)
188 follow-up of 24 months (2-95 months), 21%
of patients experienced adverse effects, with biological-ta
189 ing the first post-transplant year, 53.3%
of patients experienced at least one AR episode.
190 epolizumab versus placebo, 78% versus 32%
of patients experienced clinical benefit 1, and 87% versus
191 Median LOS was 4 days and 34%
of patients experienced complications.
192 In the DJBL group, 39%
of patients experienced at least one device-related serious
193 In group 1, 46.4%
of patients experienced any type of thrombosis versus 10.4%
194 single/dual-drug ART initially, and 45.4%
of patients experienced at least 1 episode of VF during fol
195 34.5%
of patients experienced a major complication, with highest
196 emained stable on all HRQOL scales, 38.5%
of patients experienced detectable decline on one or more s
197 ed clinical benefit 1, and 87% versus 53%
of patients experienced clinical benefit 2 (both P < .001).
198 xicities before hWBRT, and 45% (24 of 53)
of patients experienced grade 3 and 4 toxicities attributab
199 A total of 38.6%
of patients experienced exodrift greater than 10 pd.
200 Only 18.6%
of patients experienced new or recurrent ischemic events be
201 ral history of HCM-LVSD was variable, 75%
of patients experienced adverse events, including 35% exper
202 and 8.1%, respectively (P < 0.001); 37.8%
of patients experienced one or more major complication.
203 Overall, 60.9%
of patients experienced TCS; 69.7% in the target-AUC group
204 , 1.8% (rituximab) and 17.6% (fingolimod)
of patients experienced a clinical relapse (hazard ratio fo
205 Both groups
of patients experienced decreased bone turnover after KTx,
206 Nearly half
of patients experienced medication errors at the time of tr
207 lation arm, a significantly higher number
of patients experienced an improvement in their LVEF to >35
208 mong the different tests, similar numbers
of patients experienced MACE after an abnormal test result
209 Forty percent
of patients experienced a grade 3-4 treatment-related adver
210 Thirty-nine percent
of patients experienced a readmission within 12 months of a
211 Twenty-nine percent
of patients experienced a subsequent relapse.
212 Fifty-nine percent
of patients experienced ES during daytime hours (P<0.001).
213 Twenty-seven percent
of patients experienced hemoptysis.
214 Thirty-one percent
of patients experienced improvement in BiS scores postopera
215 Twelve percent
of patients experienced long-term disease control without r
216 Forty percent
of patients experienced pain reduction and better QOL at da
217 Sixty-one percent
of patients experienced pain, 74% fatigue, and 46% distress
218 Thirty-five percent
of patients experienced POAF.
219 loratory analyses to determine if subsets
of patients experienced better outcomes after stent placeme
220 ucleotide analogue therapy almost a third
of patients experienced a grade 3 or higher laboratory abno
221 Because approximately one third of
OLE patients experienced DR worsening, careful monitoring sh
222 One patient experienced a hypersensitivity reaction and deve
223 One patient experienced a paracentesis related complication
224 One patient experienced a partial recurrence 5 months after
225 One patient experienced abdominal cramps and diarrhea necess
226 One patient experienced an inflammatory response after aflib
227 One patient experienced cardiac arrest and three non-sustain
228 One patient experienced dose-limiting toxicity at 4 mg; the
229 One patient experienced febrile neutropenia but was able to
230 One patient experienced posttransplant C3 glomerulonephritis
231 One patient experienced relapse of multiple myeloma at 30 mo
232 ioperative side-effects were negligible;
one patient experienced grade-3 ulceration and infection.
233 Only
one patient experienced a dose-limiting toxicity-grade 3 tra
234 Forty-
one patients experienced EDA and, compared to the NEDA group
235 One
other patient experienced cardiac tamponade, leading to termin
236 Extracorporeal membrane
oxygenation patients experienced more clinically significant iatroge
237 Nearly 25% of
PET2-
patients experienced relapse events, demonstrating limit
238 und to be MRD negative, and the MRD-
positive patients experienced early subsequent relapse.
239 During subsequent periods in the
registry,
patients experienced further HRQL decrements: up to -9.2
240 f medium-risk patients and 6.3% of high-
risk patients experienced them ( P<0.0001).
241 None of the low-
risk patients experienced ventricular arrhythmia or unexplain
242 SAVR patients experienced significant right ventricular systo
243 Risk of Mortality score 5.6%), TAVR and
SAVR patients experienced no difference in 1-year rates of de
244 Seven patients experienced significant metabolic derangements,
245 Six patients experienced an objective response (20%), includ
246 Six patients experienced grade 2 RP, and two patients experi
247 Six patients experienced serious adverse events possibly rel
248 e maximum tolerated dose because four of
six patients experienced grade 4 neutropenia with grade 4 th
249 Thirty-
six patients experienced conversion to GMG.
250 Although
some patients experienced stable disease for 3 months, none h
251 Reduced starting dose
sorafenib patients experienced significantly lower total cumulativ
252 ive matched pairs underwent SG; single-
stage patients experienced improved outcomes in all measures e
253 n matched pairs underwent RYGB; single-
stage patients experienced shorter length of stay (LOS) (media
254 ded given that 1 in 4 previously
symptomatic patients experienced at least 1 subsequent, albeit nonle
255 Many ocular
syphilis patients experienced vision loss; however, most improved
256 Matched TA-
TAVR patients experienced more adverse procedural events, lon
257 Ten patients experienced viral relapse after treatment cessa
258 The patient experienced an increase in peripheral blood eosi
259 The patient experienced both a complete antitumor response a
260 The patient experienced systemic symptoms without mucosal sy
261 In July 2015,
the patient experienced relapse, with painful collapse of L3
262 Additionally,
the patient experienced repeated pulmonary infections with A
263 Postoperatively,
the patient experienced an improvement in neurological sympt
264 at the restaurant that the patient runs,
the patient experienced a stab-like pain on the left shoulde
265 During surgery,
the patient experienced cardiac arrest and died despite imme
266 Over the following year,
the patient experienced rapid cognitive decline with new-ons
267 32 (78%) of
the patients experienced 20% or greater reduction in the mea
268 None of
the patients experienced a CML progression.
269 and favorable prognoses, almost half of
the patients experienced a posttransplant cancer.
270 xicity occurred in 18 10%, 4%, and 3% of
the patients experienced anemia, thrombocytopenia, and leuko
271 urred in 18 patients: 10%, 4%, and 3% of
the patients experienced anemia, thrombocytopenia, and leuko
272 Overall, 6% of
the patients experienced complications.
273 None of
the patients experienced metastases nor died of iris melanom
274 None of
the patients experienced postoperative surgical site infecti
275 Half of
these patients experienced chronic pain conditions before ICU
276 ter initially robust engraftment, 3 of
these patients experienced declining donor myeloid chimerism (
277 All of
these patients experienced venous thromboembolism: 10 patients
278 ous second hit events, suggesting that
these patients experienced a 'shower' of second hit mutations
279 Three patients experienced dose-limiting toxicities: 1 at 4.0
280 did not meet the ENDA classification:
Three patients experienced anaphylaxis with different NSAIDs,
281 Thirty-
three patients experienced peripheral neuropathy, among whom,
282 Twenty-
three patients experienced >/=1 defined breakthrough cardiac a
283 Twenty-
three patients experienced graft failure, and 70 patients (7%)
284 Previous
transplant patients experienced higher incidence of readmissions (8
285 During the study phase, 10
treated patients experienced a total of 69 AEs that were unlikel
286 Twelve patients experienced grade >= 3 AEs; only one event was
287 Twelve patients experienced relapse-local (n= 6), distant (n =
288 Twenty patients experienced >1 systemic allergic reaction.
289 Two patients experienced 3 fatal parsaclisib-unrelated TEAEs
290 Two patients experienced DLTs (one each in the 80 mg and 600
291 Two patients experienced secondary graft failure attributabl
292 Two patients experienced severe retinal toxicity, including
293 Two patients experienced transient grade 3 and 4 transaminas
294 Six patients experienced grade 2 RP, and
two patients experienced grade 3 RP; all recovered after cor
295 At a median follow-up of 53 months,
two patients experienced treatment failure of the PN0 unirra
296 Over the next 3
weeks,
patient experienced progressive nausea and sharp epigast
297 isits every 6-12 months, we determined
which patients experienced progressive CKD (defined as dialysi
298 0 to 2018, 29.4% of Black and 23.0% of
White patients experienced either a 30-day HF readmission or 3
299 ion, and bleeding were also similar, but
WRF patients experienced a higher incidence of vascular deat
300 Younger patients experienced greater benefit from recent oncolog